Daiichi Sankyo Company, Limited (4568N.MX)

UPDATE 2-Japan's Daiichi Sankyo gets US FDA nod for blood cancer treatment

Daiichi Sankyo said the U.S. health regulator has approved its drug for treating newly diagnosed patients suffering from an aggressive type of blood cancer, pitting the treatment against those from rivals Novartis and Astellas. The drug, which is already approved in Japan has faced a long path to the U.S. market, with the Food and Drug Administration (FDA) declining to approve it in 2019 in a different set of acute myeloid leukemia (AML) patients and then extending its review by three months earlier this year. The treatment, branded as Vanflyta, got FDA's nod to treat adult patients with a specific gene mutation associated with increased risk of relapse in patients with AML, a type of blood and bone marrow cancer.